Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
TOKYO, Jan 18, 2023 ̵ […]
ป้ายกำกับ: patients
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass […]
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
TOKYO, Nov 24, 2022 ̵ […]
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
TOKYO, Nov 2, 2022 – […]
Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China
SHANGHAI, CHINA, Oct 10, […]
Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront
HONG KONG, Sep 28, 2022 & […]
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
TOKYO, Sep 6, 2022 – […]
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
TOKYO and RAHWAY, N.J., A […]
Lemon Healthcare Uses Blockchain Technology to Improve the Smart Healthcare Ecosystem for Patients
Seoul, Korea,June8, 2022- […]
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022
SHANGHAI, CHINA, Jun 7, 2 […]
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
TOKYO, Jun 6, 2022 – […]
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
TOKYO, May 27, 2022 ̵ […]
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
TOKYO, Mar 28, 2022 ̵ […]
Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment
Tokyo and Salt Lake City, […]
IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
HONG KONG, Mar 14, 2022 & […]
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
TOKYO, Mar 7, 2022 – […]
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
TOKYO and KENILWORTH, N.J […]
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
TOKYO, Jan 17, 2022 ̵ […]
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer’s Disease In The United States
TOKYO, Dec 21, 2021 ̵ […]
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
TOKYO, Nov 30, 2021 ̵ […]
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Strasbourg, France & […]
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, CA and HELSIN […]
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
TOKYO, Sep 27, 2021 ̵ […]
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
SHANGHAI, Sep 26, 2021 &# […]
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
TOKYO, Sep 14, 2021 ̵ […]
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NEW JERSEY, the U.S. and […]
Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
TOKYO, Aug 2, 2021 – […]
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
TOKYO and KENILWORTH, N.J […]